Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings but slightly exceeded loss expectations on an operating basis. Revenue of $187.6K beat the $0.0K expected, driven by R&D services for the Gates Foundation. GAAP EPS of -$0.20 beat the -$0.30 consensus due to lower-than-expected R&D spending, which fell 83% YoY. However, a working capital deficit of $0.2M and a delisting warning from Nasdaq highlight significant liquidity and going concern risks.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Dare Bioscience(DARE) the Revenue is 187.55 K (+985.9%), Beat estimate;the EBIT is -2.968 M (+22.46%), Beat estimate;the EPS is -0.2 (+55.56%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B985.92%
0.00B100.00%
+0.00B885.92%
EBITExceed expectations
-0.00B22.46%
-0.00B17.88%
+0.00B40.34%
EPSExceed expectations
-0.255.56%
-0.296734.07%
+0.096721.49%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf